Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.53 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 3/20 | 0.47 |
| ▸ | CBX7 | O95931 | 2/20 | 0.47 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.47 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24993896 | 0.83 | KMO (0.56) | KMOTMEM97CDY1; CDY1BCBX7CDYL2 | |
| SCHEMBL24993895 | 0.78 | KMO (0.55) | KMOTMEM97CDY1; CDY1BCBX7CDYL2 | |
| SCHEMBL10164925 | 0.76 | KMO (0.65) | KMOCDY1; CDY1BCBX7CDYL2CDYL | |
| SCHEMBL5422049 | 0.73 | KMO (0.76) | KMOCDY1; CDY1BCBX7CDYL2CDYL | |
| SCHEMBL9715947 | 0.72 | KMO (0.60) | KMOCDY1; CDY1BCBX7CDYL2CDYL | |
| SCHEMBL8190336 | 0.71 | KMO (0.58) | KMOCDY1; CDY1BCBX7CDYL2CDYL | |
| SCHEMBL8067487 | 0.71 | CHRM2 (0.55) | KMOCDY1; CDY1BCBX7CDYL2CDYL | |
| Hydrochloric Acid SCHEMBL2219338 | 0.70 | CHRM2 (0.54) | KMOCDY1; CDY1BCBX7CDYL2CDYL | |
| SCHEMBL31757917 | 0.69 | TMEM97 (0.57) | TMEM97NOS3NOS1NOS2 | |
| SCHEMBL6408326 | 0.69 | TMEM97 (0.72) | TMEM97DRD2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | KMO 3428/4885TMEM97 4597/4885CDY1; CDY1B 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.